72
Participants
Start Date
May 2, 2024
Primary Completion Date
October 1, 2027
Study Completion Date
October 1, 2034
Trastuzumab deruxtecan
T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
RECRUITING
Antoni van Leeuwenhoek, Amsterdam
Collaborators (2)
Daiichi Sankyo
INDUSTRY
AstraZeneca
INDUSTRY
The Netherlands Cancer Institute
OTHER